Navigation Links
Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/2/2007

BRISBANE, Australia, Nov. 2 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs will present a poster entitled "The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection" at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1) on Saturday, 3 November 2007.

The poster presentation will be made available on Progen's website http://www.progen-pharma.com from approximately 9am (Brisbane time) Saturday 3 November 2007.

(1) Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In a phase 2 trial in post- resection liver cancer, 160mg of PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About Progen: Progen Pharmaceuticals Limited is an Australia-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The secrets for a healthy progeny: Mother’s diet during pregnancy
2. Lizard Mothers Dress Their Progeny to Ensure Success in Later Life
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Santa Rosa, California (PRWEB) , ... May 24, ... ... management (PHM) technology, debuted a new corporate identity and website at its “Transforming ... brand, website, and other marketing enhancements reflect i2i’s ongoing success to set the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... A ... will rely heavily on their access to trusted resources, both in face-to-face interactions and ... Young Men of Color,” researchers concluded that the creative use of mobile digital devices ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... increased by 9.3 million people, or 10% over last year, according to data ... covered under group policies was comparatively stable, with a slight decrease in risk-based ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 ... Size, Share, Development, Growth and Demand Forecast to ... and Other), by Application (Drug Discovery and Development, ... Users (Pharmaceuticals, Life Science and Biotechnology, Academic and ... Market Research, the global mass spectrometry market ...
(Date:5/23/2016)... , May 23, 2016 Non-invasive ... detection of multiple diseases; ,Technology to be presented at ... Yissum Research Development Company of the Hebrew University ... a research agreement with Aurum Ventures MKI, the technology investment ... of a new diagnostic approach for early detection of ...
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
Breaking Medicine Technology: